German COVID vaccine developer BioNTech signs research deal with Australia




  • In US
  • 2022-10-06 23:42:42Z
  • By Reuters
 

SYDNEY (Reuters) - BioNTech SE, the German biotech that developed a widely used COVID-19 vaccine with Pfizer Inc, will set up research and manufacturing centres in Australia based on the same technology, the company and Australian lawmakers said on Friday.

The Nasdaq-listed company and Australia's Victoria state said they signed a partnership to create a centre, which would run clinical research of experimental messenger ribonucleic acid, or mRNA, vaccines and therapies with the aim of attracting experts from around the world.

The partnership would also involve setting up mRNA manufacturing facilities in Melbourne, based on BioNTech's modular design, the company and the state government said.

Foreign-made batches of the Pfizer-BioNTech mRNA vaccine were central to Australia's initial immunisation programme against COVID-19, but import delays created a political backlash and led to pressure for better mRNA vaccine manufacturing facilities domestically.

MRNA vaccines, which scientists say trick the body into protecting itself against an illness by copying viral proteins, are seen as a safe, speedy alternative to traditional vaccines - especially during a pandemic - since they involve no exposure to the illness.

"The state-of-the-art facility is the missing link in our mRNA ecosystem and it means Victorians can be the first in the world to potentially receive new vaccines and treatments for oncology and infectious diseases," said Victorian Minister for Innovation, Medical Research and the Digital Economy Jaala Pulford in a statement.

Science was only effective when applied "outside of the laboratories and reaches people worldwide", BioNTech Chief Executive Officer Ugur Sahin said.

"This partnership is a major step forward to enable access to mRNA technology and promote collaborations in the Asia-Pacific region," he added.

BioNTech's mRNA deal is the second for Australia, which currently has no mRNA manufacturing capability. Victoria previously said it signed a deal for Moderna to build an mRNA manufacturing facility in Monash University.

Financial terms of neither deals were disclosed.

(Reporting by Byron Kaye; Editing by Sherry Jacob-Phillips)

COMMENTS

More Related News

Australian battery metal players key to South Korea
Australian battery metal players key to South Korea's EV ambition
  • US
  • 2022-11-30 06:09:43Z

Australia will play a big role in South Korea's ambition to lead the electric vehicle batteries market and diversify from China for its battery metals needs,...

Asia Stocks Picture Mixed on Fed View, China Woes: Markets Wrap
Asia Stocks Picture Mixed on Fed View, China Woes: Markets Wrap

(Bloomberg) -- Stocks opened on a cautious note in Asia on Tuesday after Federal Reserve officials stressed that more interest rate hikes were coming and as ...

Labour turmoil sweeps Australia as inflation stirs
Labour turmoil sweeps Australia as inflation stirs 'spirit of anger'

After a decade of making up to A$200,000 a year (about US$135,000) on oil and gas rigs as a fitter and subsea equipment specialist in Western Australia, Adam...

Marine pilot arrested in Australia treated as
Marine pilot arrested in Australia treated as 'high-risk' prisoner
  • US
  • 2022-11-28 23:39:00Z

The Marine veteran's arrest came as Australia was investigating whether any of its former troops had trained Chinese military pilots.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US